Deep Bio utilizes deep learning algorithms to enhance diagnostic accuracy in pathology, specifically targeting prostate and breast cancer assessments. Their AI-driven solutions provide clinicians with precise metrics that improve treatment decision-making and address the challenges of manual evaluation in cancer diagnostics.
Funding
$8.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pathologists face challenges in accurately and consistently assessing prostate and breast cancer due to the subjective nature of manual evaluations and the increasing demand for pathological diagnoses amidst a declining number of pathologists. This variability in tumor grading can impact therapy selection and patient outcomes.
Solution
Deep Bio provides a suite of AI-driven in vitro diagnostic solutions, DeepDx®, designed to enhance the accuracy, consistency, and efficiency of cancer pathology. The company's deep learning algorithms analyze digitized whole slide images (WSIs) of H&E-stained tissue, identifying tissues and cancerous lesions, distinguishing cell nuclei and membranes, classifying histologic tumor types, estimating gene mutations, and predicting patient prognoses. By providing metrics that are difficult to measure manually, Deep Bio empowers clinicians to optimize treatment decisions and improve patient outcomes. The company's solutions are developed in collaboration with healthcare professionals and are integrated into digital pathology platforms to ensure stable delivery and continuous improvement.
Target Audience
The primary target audience includes pathologists, healthcare institutions, and digital pathology platform providers seeking to improve the accuracy and efficiency of cancer diagnoses and treatment decisions.
Features
- AI-based in vitro diagnostic software for prostate and breast cancer pathology
- Deep learning algorithms for image analysis, tissue identification, and lesion detection
- Automated Gleason grading for prostate cancer and histological grading for breast cancer
- Algorithms for estimating gene mutations and predicting patient prognoses
- Integration with digital pathology platforms for seamless workflow
- Compliance with data regulations and robust security measures (ISO 27001 certified)
- Solutions feature robust security measures in line with the South Korean Ministry of Food and Drug Safety (MFDS) cybersecurity checklist
- Cloud services comply with HIPAA regulations, ensuring secure storage, transmission, and processing of protected health information (PHI).